Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects

Exclusion Criteria

• •1. Male and female subjects, aged 18 to 60 years, inclusive.
• •2. Body mass index between 18 and 32 kg/m2, inclusive, with body weight \> 45 kg for females and \>50 kg for males .
• •3. Serum LDL-C ≥100mg/dL (2.6 mmol/L) at screening and Day -1.
• •4. Fasting triglycerides \< 400 mg/dL (\<4.52 mmol/L) at screening and Day -1.
• •5. Adequate complete blood counts (complete blood counts \[CBCs\]; if outside the reference range, CBC values that are not clinically relevant and are acceptable to the Investigator).
• •6. Female subjects are eligible to participate if they are confirmed either not women of child-bearing potential (WOCBP), or have a negative urine pregnancy test at Day 1, are not breastfeeding, and willing and able to abide by the contraception guidelines (signing the ICF).
• •7. Male subjects who can produce viable sperm are eligible to participate if they agree to use an adequate method of contraception as per the contraceptive guidance in Appendix 3 from Screening (signing the ICF) until at least 3 months post dose. Subjects with a partner(s) who is (are) not of childbearing potential are exempt from these requirements.
• •8. Male subjects with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration. In addition, male subjects must refrain from donating sperm from Screening (signing the ICF) until at least 3 months post dose.
• •9. Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent.